COMPASS Pathways plc

Equities

CMPS

US20451W1018

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-07 EDT			5-day change	1st Jan Change
6.94 ^USD	+0.43%		-5.96%	-20.69%

06-05	Morgan Stanley Adjusts COMPASS Pathways Price Target to $23 From $30, Maintains Overweight Rating	MT
06-04	FDA panel to review psychedelic drug MDMA for first time	RE

COMPASS Pathways plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2022

February 28, 2023 at 07:03 am

COMPASS Pathways plc reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 30.93 million compared to USD 25.65 million a year ago. Basic loss per share from continuing operations was USD 0.73.

Latest news about COMPASS Pathways plc

Morgan Stanley Adjusts COMPASS Pathways Price Target to $23 From $30, Maintains Overweight Rating	06-05	MT
FDA panel to review psychedelic drug MDMA for first time	06-04	RE
Clarify Pharma confirms name change to File Forge	05-22	AN
Transcript : COMPASS Pathways plc - Shareholder/Analyst Call	05-09
Transcript : COMPASS Pathways plc, Q1 2024 Earnings Call, May 08, 2024	05-08
COMPASS Pathways plc Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Compass Pathways plc Reports Top-Line Results from an Open-Label Phase 2 Study Evaluating the Safety and Tolerability of Investigational COMP360 Psilocybin Treatment in 22 Patients with Post-Tail Stress Disorder	05-08	CI
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement to Inform the Training of Healthcare Providers and Delivery Model for Comp360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression	04-29	CI
Compass Pathways Insider Sold Shares Worth $597,964, According to a Recent SEC Filing	04-18	MT
Compass Pathways Insider Sold Shares Worth $597,964, According to a Recent SEC Filing	04-18	MT
Clarify Pharma to change name to File Forge Technology	04-17	AN
Compass Pathways Insider Sold Shares Worth $461,332, According to a Recent SEC Filing	04-02	MT
Compass Pathways Insider Sold Shares Worth $461,332, According to a Recent SEC Filing	04-02	MT
Compass Pathways Insider Sold Shares Worth $445,552, According to a Recent SEC Filing	04-01	MT
Compass Pathways Insider Sold Shares Worth $445,552, According to a Recent SEC Filing	04-01	MT
Morgan Stanley Initiates COMPASS Pathways at Overweight With $30 Price Target	04-01	MT
ADRs End Lower; NuCana Slides 15%	03-28	DJ
Compass Pathways Co-Founders Step Down From Board; David Norton Named Interim Chair; Shares Fall	03-28	MT
COMPASS Pathways plc Announces Board Changes	03-28	CI
Compass Pathways Insider Sold Shares Worth $704,821, According to a Recent SEC Filing	03-15	MT
Compass Pathways Insider Sold Shares Worth $704,821, According to a Recent SEC Filing	03-15	MT
Transcript : COMPASS Pathways plc, Q4 2023 Earnings Call, Feb 29, 2024	02-29
COMPASS Pathways plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29	CI
COMPASS Pathways plc Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Compass Pathways Insider Sold Shares Worth $609,862, According to a Recent SEC Filing	02-27	MT

Chart COMPASS Pathways plc

Duration

Period

More charts

Company Profile

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 psilocybin treatment. COMP360 is its proprietary psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Companyâs initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.94 USD

Average target price

40.38 USD

Spread / Average Target

+481.77%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
COMPASS PATHWAYS PLC	-20.69%	475M
MODERNA, INC.	+51.85%	57.87B
LONZA GROUP AG	+41.42%	40.25B
IQVIA HOLDINGS INC.	-5.25%	39.94B
CELLTRION, INC.	-5.16%	28.54B
ICON PUBLIC LIMITED COMPANY	+12.79%	26.4B
ALNYLAM PHARMACEUTICALS, INC.	-20.18%	19.33B
MEDPACE HOLDINGS, INC.	+30.88%	12.4B
BIO-TECHNE CORPORATION	+0.61%	12.23B
UNITED THERAPEUTICS CORPORATION	+25.06%	12.2B

Other Biotechnology & Medical Research